Integrum AB (publ) has published its Annual Report for the financial year 1 May 2025 to 30 April 2026.

The Annual Report is available on the company’s website:
https://investors.integrum.se/en/corporate-governance/bolagsstammor/agm-2026

A PDF version of the Annual Report is also attached to this press release.

For further information, please contact:
Louise Wåhlin, CFO
Tel: +46 734 63 73 03
Email: louise.wahlin@integrum.se

Certified Adviser
DNB Carnegie Investment Bank AB (publ)
+46 8-588 685 70
certifiedadviser@dnbcarnegie.se

About Us
Integrum AB is a publicly traded company (INTEG B: Nasdaq First North Growth Market) based outside of Gothenburg, Sweden. Since 1990, its OPRA™ Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore eliminating the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA™ Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit https://integrum.se/.

Attachments
Årsredovisning 2025 2026